In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Meixia CheState Key Laboratory of Pharmaceutical Biotechnology, Department of Oncology, Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, 210023 Nanjing, China.ORCID 0000-0002-4515-1414 Shaela FieldsDivision of Molecular Oncology/Cancer Biology Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-2213-5515 Siqi YiDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Judith HyleDivision of Molecular Oncology/Cancer Biology Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Mengli ZhangCyrus Tang Medical Institute, National Clinical, Research Center for Hematologic Disease, State Key Laboratory of Radiation Medicine and Protection, Collaborative Innovation Center of Hematology, Suzhou Medical College, Soochow University, 215123 Suzhou, Jiangsu, China.ORCID 0009-0008-0801-485X Beisi XuCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-0099-858X Yong ChengDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Peng XuCyrus Tang Medical Institute, National Clinical, Research Center for Hematologic Disease, State Key Laboratory of Radiation Medicine and Protection, Collaborative Innovation Center of Hematology, Suzhou Medical College, Soochow University, 215123 Suzhou, Jiangsu, China.ORCID 0000-0002-7573-4813 Yajun JiangState Key Laboratory of Pharmaceutical Biotechnology, Department of Oncology, Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, 210023 Nanjing, China.ORCID 0000-0002-0886-292X Chunliang LiDivision of Molecular Oncology/Cancer Biology Program, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-5938-5510 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The molecular mechanisms by which KMT2A-rearranged (KMT2A-r) leukemias maintain the oncogenic
Indexed as
DNA, Single-Strandedfms-Like Tyrosine Kinase 3Gene Expression Regulation, LeukemicGene RearrangementHistone-Lysine N-MethyltransferaseLeukemiaMyeloid-Lymphoid Leukemia ProteinRNA-Binding ProteinsCell Line, TumorHumansProtein BindingDNA, Single-StrandedFLT3 protein, humanfms-Like Tyrosine Kinase 3Histone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinRNA-Binding Proteins
Identifiers
PMID42566532
PMCPMC13450212
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390